Stroke Data project

Stroke data solutions

Novel data-intensive innovations for stroke prevention and diagnostics

Expected results

  1. Patient-facing solution to support stroke patient from hospital to rehabilitation and back home 
  2. Professional-facing solution to support expert team decision making in from emergency care to hospital, rehabilitation and back home
  3. Feasibility tests for the co-created solutions
  4. Prediction model to show the solution impact
  5. Business model alternatives that help companies and hospitals to take the Stroke-Data solutions to the selected Nordic, Asian, US and Australian markets 

Commercial exploitation

The commercial exploitation of the Stroke-DATA project is in two directions or paths: The first exploitation path is the collaboration of the Stroke-DATA ecosystem to capture the global stroke prevention and diagnostic market ($44.5 billion in 2025). 


The second exploitation path is that each consortium partner will be able to exploit the technical solutions developed in the project in other domains. All aspects of this work are designed to be applicable to other areas of the professional healthcare business domain. Expandability will be realized directly by the domain shift aspect of this work and by exploiting the developed tools in a new environment.  

Stroke is the fourth leading cause of death in Finland and Europe. There are 20 000 stroke cases in Finland alone each year. Thus, on average, on any day, 55 people in Finland get a stroke, and one-third of these people are still at working age. 25% of these people recover normally, but 15% of them will stay permanently in the nursing home.


Taking care of these stroke patients is very costly to our society. The direct yearly cost of stroke care is 500 million euros. Including the indirect costs, the total cost of stroke is 1100 million euros, yearly.

There is an urgent need for the early and correct diagnosis of patients who experience a TIA and/or Stroke. The key to addressing this need lies in the combination of information in ways that have not been possible until now, and extract actionable recommendations from this information.


This is especially a field where modern AI approaches can help. It has also been predicted that one of the top areas in which artificial intelligence will be most successfully used will be decision management in healthcare.

Stroke-data will capitalize on the recent advancements in AI, and, together with the richness of data, provide decision management support tools.


Such an approach can be realised by a clinical decision support system with tailored multimodal neuroimaging technologies (i.e., capacitive and microwave imaging and functional Near-Infrared Spectroscopy [NIRS]), diagnostic algorithms, and AI for diagnostics of cerebrovascular disorders (especially differentiate brain hemorrhage from ischemic stroke already when and where they occur in the field), triaging, and acute management of cerebrovascular conditions.


Additionally, help can be obtained by radically new measurement techniques, such as a solution that includes advanced sensor technology to be combined with transcranial Doppler ultrasound (TCD) scan data to examine the narrowing of the carotid arteries as well as asymptomatic and symptomatic microembolic signals to diagnose and prevent stroke.

The development of stroke prevention and diagnostics solutions requires ecosystemic co-creation and new types of development practices between researchers, companies, and hospitals from different countries. In particular, it cannot be done without multidisciplinary expertise from technology, business, and medical fields.

This all is possible only in our Stroke-DATA consortium that involves the advanced companies from Finland, National neuro centres from Finland and neurologists from Oulu (OUH) and Kuopio University Hospitals (KUH) /the University of Eastern in Finland (UEF).


The business model validation for Asia and Nordic countries will be done together with several hospitals, National University, Neurocentre and innovation players from Singapore, Norway, Sweden as well as Shanghai University; SHU Global and SILC Business School in China.

The target is also to create own funding proposals in Singapore, Norway and Sweden to get resources in order to collect additional data for Stroke-DATA solution validation.

Additional international collaboration in the area of Stroke prevention and diagnostics will be built with RMIT and Griffith Universities in Australia as well as Mayo Clinic and Arizona State University in the US.